Tag Archives: Neuroscience

Some observations regarding companies that should know better

Welcome to the Jurassic Petting Zoo Dinosaurs once roamed and ruled the earth, but they couldn’t take the heat. Similarly, Pfizer is exiting neuroscience R&D, with the exception of a couple of pain and rare disease programs, since they reside … Continue reading

Posted in Big Pharma, BioFollies, Biotech | Tagged , , , , , , , , , , | Leave a comment

Two Incompatible Truths

There is major news regarding the neurotherapeutics aspirations for two Big Pharmas, Roche and Bristol Myers Squibb. Roche has had sufficient success in two of the three programs whose outcome was to dictate their future course vis-a-vis CNS (gantenerumab and … Continue reading

Posted in Big Pharma, BioFollies | Tagged , , | Leave a comment

Teva in Turmoil

Back in January, Teva Pharmaceuticals had made our Best News of 2012 roster, based on its announced intention to revamp and refocus its R&D on CNS and respiratory disorders, and to invest $10 billion over the next five years to … Continue reading

Posted in Big Pharma, BioFollies | Tagged , , | Leave a comment

New Definitions for Neuroscience: Data-fracking

Data-fracking is the fracturing of a dataset by the application of a pressurized search through as many datapoints as is necessary to find one that has the appearance of being positive. Typically, data is combined with cortisol and caffeine, and … Continue reading

Posted in Big Pharma, BioFollies, Biotech, Muddled Media | Tagged , , , | Leave a comment

Weather Update

The National Weather Service reports that there are some breaks in the thick layer of clouds and fog which has covered the CNS space for much of the past year. While there are not yet clear signs of a summer … Continue reading

Posted in Big Pharma, Biotech, Science | Tagged , , , , | Leave a comment

Two CNS Acquisitions

Two companies had buyouts announced today: One is clearly good news, the second may be good for shareholders, we are not sure about the ramifications for its CNS work. 1) Newron is acquiring neurogenesis-specialist NeuroNova for about $20 million in … Continue reading

Posted in Uncategorized | Tagged , , , , , | Leave a comment

Bexarotene Furor

Last week’s publication in Science of a paper by Cramer et al on the effects of bexarotene in transgenic mouse models of Alzheimer’s stirred up quite the media storm, and a flurry of requests from AD families for off-label prescriptions … Continue reading

Posted in Science | Tagged , , , , | 6 Comments